3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026
Source: zacks
Large-cap pharmaceuticals have risen 22.6% year to date, outpacing the Medical sector (+8.5%) and S&P 500 (+7.2%); the article highlights Bayer (+41.7%), Eli Lilly (+26.0%) and Novartis (+17.9%) as stocks to watch. Growth drivers include new products, strong GLP-1 demand and renewed dealmaking, while Lilly has announced more than $20 billion in biotech deals this year. Risks include patent expirations, competition and pricing pressure—Lilly's worldwide realized prices fell 15% in Q3—as well as uncertainty over tariffs of up to 100% on certain imported patented pharmaceuticals and ingredients.⟂
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
- Jim Cramer's top 10 things to watch in the stock market Monday
- Adagene completes enrollment in phase 2 trial of muzastotug
- Moderna: 3 Key Takeaways for Long-Term Investors
- MRK's 2027 Outlook Challenging, Long-Term Prospects Promising